208 related articles for article (PubMed ID: 19116379)
1. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.
Hellberg V; Wallin I; Eriksson S; Hernlund E; Jerremalm E; Berndtsson M; Eksborg S; Arnér ES; Shoshan M; Ehrsson H; Laurell G
J Natl Cancer Inst; 2009 Jan; 101(1):37-47. PubMed ID: 19116379
[TBL] [Abstract][Full Text] [Related]
2. Cochlear pharmacokinetics of cisplatin: an in vivo study in the guinea pig.
Hellberg V; Wallin I; Ehrsson H; Laurell G
Laryngoscope; 2013 Dec; 123(12):3172-7. PubMed ID: 23754209
[TBL] [Abstract][Full Text] [Related]
3. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
4. Blood flow-independent accumulation of cisplatin in the guinea pig cochlea.
Miettinen S; Laurell G; Andersson A; Johansson R; Laurikainen E
Acta Otolaryngol; 1997 Jan; 117(1):55-60. PubMed ID: 9039482
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures.
Dammeyer P; Hellberg V; Wallin I; Laurell G; Shoshan M; Ehrsson H; Arnér ES; Kirkegaard M
Acta Otolaryngol; 2014 May; 134(5):448-54. PubMed ID: 24702224
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin.
Saito T; Manabe Y; Saito H
ORL J Otorhinolaryngol Relat Spec; 1995; 57(5):250-5. PubMed ID: 8587776
[TBL] [Abstract][Full Text] [Related]
7. Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs.
Saito T; Zhang ZJ; Yamada T; Yamamoto T; Shibamori Y; Saito H
Acta Otolaryngol; 1997 Jan; 117(1):61-5. PubMed ID: 9039483
[TBL] [Abstract][Full Text] [Related]
8. The effects of ototoxic drugs on mechano-electric transduction channels in chick cochlear hair cells.
Kimitsuki T; Nakagawa T; Hisashi K; Komune S; Uemura T
Eur Arch Otorhinolaryngol; 1994; 251 Suppl 1():S53-6. PubMed ID: 11894776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.
Cashin PH; Ehrsson H; Wallin I; Nygren P; Mahteme H
Eur J Clin Pharmacol; 2013 Mar; 69(3):533-40. PubMed ID: 22983312
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.
Schweitzer VG
Laryngoscope; 1993 Apr; 103(4 Pt 2):1-52. PubMed ID: 8464301
[TBL] [Abstract][Full Text] [Related]
11. Distribution of platinum in blood and perilymph in relation to cisplatin induced ototoxicity in the guinea pig.
Sepmeijer JW; Klis SF
Hear Res; 2009 Jan; 247(1):34-9. PubMed ID: 18955125
[TBL] [Abstract][Full Text] [Related]
12. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
13. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
[TBL] [Abstract][Full Text] [Related]
16. Ototoxicity among cisplatin, carboplatin, and oxaliplatin in zebrafish model.
Li KH; Zhao YY; Cheng HL; Yang JJ; Chien CY
Environ Toxicol; 2024 Jul; 39(7):4058-4065. PubMed ID: 38661261
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals.
Dehne N; Lautermann J; Petrat F; Rauen U; de Groot H
Toxicol Appl Pharmacol; 2001 Jul; 174(1):27-34. PubMed ID: 11437646
[TBL] [Abstract][Full Text] [Related]
18. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig.
Laurell G; Andersson A; Engström B; Ehrsson H
Cancer Chemother Pharmacol; 1995; 36(1):83-6. PubMed ID: 7720182
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
20. Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.
Tippayamontri T; Kotb R; Paquette B; Sanche L
Invest New Drugs; 2011 Dec; 29(6):1321-7. PubMed ID: 20658169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
